Introducing: The Landmark Series

[1]  G. Karakousis,et al.  The Landmark Series: Randomized Trials Examining Surgical Margins for Cutaneous Melanoma , 2019, Annals of Surgical Oncology.

[2]  R. Berman,et al.  The Landmark Series: Non-melanoma Skin Cancers , 2019, Annals of Surgical Oncology.

[3]  M. Faries,et al.  The Landmark Series: MSLT-1, MSLT-2 and DeCOG (Management of Lymph Nodes) , 2019, Annals of Surgical Oncology.

[4]  Michael E. Egger,et al.  The Sunbelt Melanoma Trial , 2019, Annals of Surgical Oncology.

[5]  J. Zager,et al.  The Landmark Series: Regional Therapy of Recurrent Cutaneous Melanoma , 2019, Annals of Surgical Oncology.

[6]  A. Gesierich,et al.  Completion Dissection or Observation for Sentinel‐Node Metastasis in Melanoma , 2017, The New England journal of medicine.

[7]  M. Ally,et al.  Non‐melanoma skin cancers , 2015 .

[8]  C. Antonescu,et al.  Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial , 2009, The Lancet.

[9]  L Påhlman,et al.  Improved survival with preoperative radiotherapy in resectable rectal cancer. , 1997, The New England journal of medicine.

[10]  M. Mihm,et al.  Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. , 1996, Annals of surgery.

[11]  B Fisher,et al.  Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. , 1985, The New England journal of medicine.

[12]  K. McMasters,et al.  The Sunbelt Melanoma Trial. , 2019, Annals of surgical oncology.